ASIX at a glance
AdvanSix Inc. (ASIX, SEC CIK 1673985) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AdvanSix Inc. (ASIX) reported revenue of $1.5 billion (up 0.3% from FY2024) and net income of $49.3 million. Diluted EPS was $1.80.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding AdvanSix Inc. (ASIX) shares worth $159.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.5B
- +0.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $159.8M · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 8.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors from the 2025 Form 10-K
- Commodity price volatility risk, affecting raw-material costs and margins
- Environmental, health, and safety compliance risk, including potential liability
- Cyclical demand risk, exposing results to nylon and chemical market conditions
- Customer concentration risk, increasing dependence on major buyers
Management Discussion & Analysis
- Q3 revenue $430.8M, up 15.0% YoY from $374.5M, driven by pricing, partially offset by 1.8% lower volume
- Gross margin 2.6% vs 6.8% YoY, pressured by lower production rates and raw-material cost pass-through
- Plant Nutrients strongest nine-month pricing contributor, while Nylon Solutions caprolactam sales drove lower volume
- Operating cash flow $42.7M vs $59.1M YoY, with $74.9M capital spending and $22.6M cash on hand
- 2026 capital expenditures expected at approximately $90M, with raw-material costs, production disruptions, and customer demand as headwinds
AI summary of the ASIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Quarterly cash dividend declared at $0.16 per share
- Payment scheduled for December 1, 2026
Item EX-99.1: Item EX-99.1
- 3Q26 sales $430.8M, up 15%, but net loss $7.6M and adjusted EPS $(0.24) versus $0.08
- Adjusted EBITDA $14.6M, down $10.1M, with margin contracting to 3.4% from 6.6%
Item 2.02: Results of Operations and Financial Condition
- Press release announces AdvanSix financial results for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for earnings, revenue, margins and outlook details
Item 1.02: Termination of a Material Definitive Agreement
- Existing Credit Agreement loans fully repaid August 14, 2026
- Accrued interest and fees paid alongside principal
Item 1.01: Entry into a Material Definitive Agreement
- New senior secured facilities: $275 million revolver plus $150 million term loan, both maturing August 14, 2031
- $295 million borrowed at closing, including $145 million revolver and $150 million term loan, with approximately $17 million cash
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 contains no standalone debt terms
- Financial obligation details appear under Item 1.01, requiring review of the related material agreement disclosure
Item 8.01: Other Events
- Quarterly cash dividend of $0.16 per share declared by AdvanSix’s Board
- September 1, 2026 payment date for shareholders of record August 18, 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- 2Q26 sales $421.3M, up 3%, but volume fell 15%; pricing increased 18% amid higher benzene, propylene, and sulfur costs
- Net income plunged 90% to $3.2M; adjusted EPS declined 85% to $0.19
AI summaries of ASIX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ASIX
Don't miss the next ASIX filing
- Alerts as it files. A push when ASIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASIX, by share count.
- Ask anything. An AI agent that reads every ASIX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Williams Patrick | A | Oct 6, 2026 | 785 | $16.70 |
| Williams Patrick | A | Jun 30, 2026 | 660 | $19.88 |
| Lovett Gena C | A | Jun 22, 2026 | 6,207 | - |
| Roberts Daryl | A | Jun 22, 2026 | 6,207 | - |
| Bird Jeffrey J. | A | Jun 22, 2026 | 6,207 | - |
| Karran Todd D. | A | Jun 22, 2026 | 6,207 | - |
| NEWMAN DONALD P | A | Jun 22, 2026 | 6,207 | - |
| Spurlin Sharon | A | Jun 22, 2026 | 6,207 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.5B | $1.5B | $1.5B |
| Net Income | $54.6M | $44.1M | $49.3M |
| Net Margin | 3.6% | 2.9% | 3.2% |
| Balance Sheet | |||
| Total Assets | $1.5B | $1.6B | $1.7B |
| Equity | - | $774.6M | $815.2M |
| ROE | - | 5.7% | 6.0% |
| Per Share | |||
| EPS | $1.95 | $1.62 | $1.80 |
| Cash Flow | |||
| Operating CF | $117.5M | $135.4M | $122.9M |
| CapEx | $107.4M | $133.7M | $116.4M |
Source: XBRL data in AdvanSix Inc. (ASIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ASIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $159.8M |
| Q2 2026 | 27 | $206.5M |
| Q1 2026 | 27 | $239.6M |
| Q4 2025 | 28 | $192.3M |
| Q3 2025 | 27 | $243.0M |
| Q2 2025 | 28 | $298.0M |
| Q1 2025 | 25 | $181.0M |
| Q4 2024 | 21 | $205.8M |
- Citadel Advisors LLC+363.6K (+171%)
- BlackRock+194.8K (+8%)
- D.E. Shaw & Co+85.0K (+44%)
- JPMorgan Chase & Co+77.7K (+62%)
- Vanguard Portfolio Management LLC+55.7K (+16%)
- Goldman Sachs Group−203.5K (-37%)
- AQR Capital Management−148.9K (-21%)
- Morgan Stanley−97.0K (-20%)
- Two Sigma Investments−40.4K (-7%)
- Franklin Resources−27.4K (-27%)
- Prudential Financial+12.6K
- TOMPKINS FINANCIAL CORP+1.0K
- FMR LLC (Fidelity)−658.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 8, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 14, 2026 | - | - | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| SC 13G | May 14, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 8, 2026 | - | Analysis | |
| 4 | Apr 29, 2026 | - | - | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 26, 2026 | - | - | - |
Related Health Care companies
- PCT · PureCycle Technologies, Inc.Plastic Materials, Synth Resins & Nonvulcan Elastomers
- ROG · ROGERS CORPPlastic Materials, Synth Resins & Nonvulcan Elastomers
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
ASIX SEC filings: frequently asked questions
Which institutions hold ASIX stock?
As of September 30, 2026, the largest AdvanSix Inc. (ASIX) holders among the 13F filers tracked by SignalX were BlackRock ($42.0 million), Dimensional Fund Advisors ($22.8 million), Vanguard Capital Management LLC ($18.1 million), State Street Corp ($9.4 million), Citadel Advisors LLC ($9.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASIX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AdvanSix Inc. (ASIX) reported revenue of $1.5 billion (up 0.3% from FY2024) and net income of $49.3 million. Diluted EPS was $1.80. The figures come from the XBRL data in the 10-K.
What did ASIX report in its latest 8-K?
AdvanSix Inc. (ASIX) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Quarterly cash dividend declared at $0.16 per share.
What are the latest ASIX SEC filings?
AdvanSix Inc. (ASIX) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 8, 2026.
What is ASIX's SEC CIK number?
AdvanSix Inc. (ASIX)'s SEC Central Index Key (CIK) is 1673985. EDGAR lists every ASIX filing under that number.
Ask anything about ASIX
The research agent reads ASIX's filings, financials, insider trades and 13F holders, then answers with sources.